Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2014

01-09-2014 | Letter to the Editor

A 5-day: the favourable way?

Authors: Maeve A. O’Reilly, Cathy McHale, Ahmed Almazmi, Abdul Hameed, Dalia Benjamin, Niamh O’Connell, Philip Murphy, John Quinn, Patrick Thornton, Peter O’Gorman, Hana Frankova, Jeremy Sargent, Estelle Verburgh, John McHugh, Pamela Evans, Helen Enright

Published in: Annals of Hematology | Issue 9/2014

Login to get access

Excerpt

Dear editor, …
Literature
1.
Pierdomenico F, Esteves S, Almeida A (2013) Efficacy and tolerability of a 5-day azacytidine dose-intensified regimen in higher-risk MDS. Ann Hematol 92:1201–1206PubMedCrossRef
2.
Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604–3608PubMedCrossRef
3.
Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850–1856PubMedCrossRef
4.
Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascotto C, Inverizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510PubMedCrossRef
5.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425PubMedCrossRef
6.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gatterman N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 10:223–232PubMedCentralPubMedCrossRef
7.
List AF, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Gore S, Bennett JM, Silverman LR, Backstrom J, Allen AR, Beach CL (2008) Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol. 26: Abstract 7006
Metadata
Title
A 5-day: the favourable way?
Authors
Maeve A. O’Reilly
Cathy McHale
Ahmed Almazmi
Abdul Hameed
Dalia Benjamin
Niamh O’Connell
Philip Murphy
John Quinn
Patrick Thornton
Peter O’Gorman
Hana Frankova
Jeremy Sargent
Estelle Verburgh
John McHugh
Pamela Evans
Helen Enright
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-2005-9

Other articles of this Issue 9/2014

Annals of Hematology 9/2014 Go to the issue

Original Article

Hydroxycarbamide modulates components involved in the regulation of adenosine levels in blood cells from sickle-cell anemia patients

Original Article

Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme

Original Article

Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study

Original Article

Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)

Letter to the Editor

Successful treatment of high-risk acute promyelocytic leukemia in very elderly patients using all-trans retinoic acid plus reduced-dose idarubicin

Letter to the Editor

Is there still a place for itraconazole prophylaxis in high-risk hematology patients?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits